Efficacy and safety of intranasal budesonide in the treatment of perennial rhinitis in adults and children.
The efficacy and safety of intranasal budesonide were evaluated in a placebo-controlled double-blind study of 51 children (6 to 18 years) and 48 adults with perennial (allergic or nonallergic) rhinitis. The trial commenced with a 2-week baseline period without treatment for perennial rhinitis. This was followed by a treatment period of 4 weeks. Treatment was either intranasal budesonide 200 micrograms bid or matching placebo bid. Nasal symptoms were rated daily on a scale from 0 (absent) to 3 (severe). Safety was monitored by laboratory assessments (hematology, blood chemistry, urinalysis) as well as by rhinoscopy and recording of adverse events. Budesonide reduced the nasal symptoms as compared with baseline. The reduction was greater than in the placebo group and symptoms were improved significantly on budesonide treatment compared with placebo. Laboratory assessments demonstrated no differences between budesonide and placebo. Adverse responses to intranasal budesonide were few and minor, and compliance was high. Intranasal budesonide, 200 micrograms bid, thus appears to be efficacious, highly acceptable, and safe for the treatment of perennial rhinitis.
Division of Allergy and Immunology, Kingston General Hospital, Ontario, Canada.
J H
JH
Day
C B
CB
Andersson
M P
MP
Briscoe
D000281:Administration, Intranasal; D000293:Adolescent; D000328:Adult; D019819:Budesonide; D002648:Child; D004311:Double-Blind Method; D005938:Glucocorticoids / Q000378:metabolism; D006801:Humans; D010349:Patient Compliance; D011282:Pregnenediones / Q000008:administration & dosage* / Q000592:standards / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy*
D005938:Glucocorticoids; D011282:Pregnenediones; D019819:Budesonide